Related Experiment Video

Updated: Oct 23, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Prospects for the therapeutic use of anticancer vaccines

R S Chamberlain1

  • 1Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. chamberr@mskcc.org

Drugs
|April 8, 1999
PubMed

Insights

Cancer immunotherapy, despite a century of research, is emerging. Advances in tumor immunology and novel vaccine strategies show promise, but challenges remain for effective cancer treatment.

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Cancer immunotherapy research began over a century ago.
  • Early attempts at immunostimulation for cancer treatment yielded limited success.
  • Recent progress in tumor immunology has spurred new vaccine development.

Purpose of the Study:

  • To review the historical context and current advancements in cancer immunotherapy.
  • To discuss novel vaccine approaches and their potential clinical applications.
  • To identify remaining challenges and future research directions in cancer vaccines.

Main Methods:

  • Review of historical and recent literature on cancer immunotherapy and vaccine development.
  • Identification of various vaccine platforms including tumor cells, carbohydrates, peptides, heat-shock proteins, DNA, recombinant bacteria, and viruses.
  • Analysis of clinical results and immunological/host obstacles.

Main Results:

  • Despite historical efforts, cancer immunotherapy remains in its early stages.
  • Novel vaccine strategies utilizing tumor antigens, DNA, and recombinant vectors show promising clinical results.
  • Significant immunological and host-related obstacles hinder the widespread success of cancer vaccines.

Conclusions:

  • Advances in identifying cancer regression antigens enable novel vaccine strategies.
  • Various vaccine platforms (e.g., peptide, DNA, viral) offer potential for cancer treatment.
  • Further research is crucial to overcome existing obstacles and optimize cancer vaccine efficacy.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...